The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 03, 2007
Filed:
Apr. 24, 2002
Fons Bosman, Opwijk, BE;
Erik Depla, Destelbergen, BE;
Geert Deschamps, Aalter, BE;
Erwin Sablon, Merchtem, BE;
Manfred Suckow, Düsseldorf, DE;
Isabelle Samson, Heule, BE;
Gert Verheyden, Holsbeek, BE;
Fons Bosman, Opwijk, BE;
Erik Depla, Destelbergen, BE;
Geert Deschamps, Aalter, BE;
Erwin Sablon, Merchtem, BE;
Manfred Suckow, Düsseldorf, DE;
Isabelle Samson, Heule, BE;
Gert Verheyden, Holsbeek, BE;
Innogenetics N.V., Ghent, BE;
Abstract
The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in that on average up to 80% of their N-glycosylation sites are core-glycosylated. Of these N-glycosylated sites more than 70% are glycosylated with an oligomannose having a structure defined by Man(8 to 10)-GlcNAc(2). Furthermore, the ratio of the oligomannose with structure Man(7)-GlcNAc(2) over the oligomannose with structure Man(8)-GlcNAc(2) is less than or equal to 0.45. Less than 10% of the oligomannoses is terminated with an α1,3 linked mannose. The HCV envelope proteins of the invention are particularly suited for diagnostic, prophylactic and therapeutic purposes. A suitable eukaryotic cell for production of the HCV envelope proteins of the invention is acell.